This combination also increases tumor-infiltrating CD4+ and CD8+ T cells, particularly when used in conjunction with low-dose docetaxel, which is associated with the PI3K/AKT/NFKB-P65/PD-L1 signaling pathway (78). This evidence concerns the gene CD274 and neoplasm.